mRNA expression of S100A8 as a prognostic marker for progression of non-muscle-invasive bladder cancer

Korean Journal of Urology

Volumn 51, Issue 1, 2010, Pages 15-20

  Ha, Yun Sok ^a   Kim, Min Ju ^a   Yoon, Hyung ^a   Kang, Ho Won ^a   Kim, Yong June ^a   Yun, Seok Joong ^a   Lee, Sang Cheol ^a   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

Author keywords

Biological tumor markers; Polymerase chain reaction; S100A8 protein; Urinary bladder neoplasms

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN A; MESSENGER RNA;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EVALUATION; CONFIDENCE INTERVAL; FEMALE; GENE EXPRESSION; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSURETHRAL RESECTION;

EID: 76749121817     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.1.15     Document Type: Article

References (29)

1. The statistics report: the incidence of cancer on 2003-2005 and the survival rate on 1993-2005, http://www.ncc.re.kr (accessed Apr 1, 2009). National Cancer Center; 2009.
2. Messing EM. Urothelial tumors of the bladder. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 9th ed. Philadelphia: Saunders; 2007; 2426-7.
3. Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000;163:758-60.
4. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14.
5. Quan C, Park MS, Jo SW, Lee SC, Kim WJ. Effects of transforming growth factor-beta1 and its receptor on the development, recurrence and progression of human bladder cancer. Korean J Urol 2006;47:426-35.
6. Ha YS, Yun SJ, Kim YJ, Lee SC, Kim WJ. Utility of Smo as a prognostic marker for human bladder tumors. Korean J Urol 2007; 48:997-1003.
7. Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996;21:134-40.
8. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322:1111-22.
9. Schäfer BW, Wicki R, Engelkamp D, Mattei MG, Heizmann CW. Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 1995;25:638-43.
10. Schutte BC, Carpten JD, Forus A, Gregory SG, Horii A, White PS. Report and abstracts of the sixth international workshop on human chromosome 1 mapping 2000. Iowa City, Iowa, USA. 30 September-3 October 2000. Cytogenet Cell Genet 2001;92:23-41.
11. Yong HY, Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res 2007;30:75-81.
12. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res 2007;27:3051-8.
13. Tolson JP, Flad T, Gnau V, Dihazi H, Hennenlotter J, Beck A, et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 2006;6:697-708.
14. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008;34:357-64.
15. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2003;15:227-33.
16. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002;87:13-5.
17. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-30.
18. Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ 1996;312:1079.
19. Hsieh HL, Schäfer BW, Sasaki N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 2003;307: 375-81.
20. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005;46: 256-69.
21. Rafii S, Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol 2006;8:1321-3.
22. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64:4040-8.
23. Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 2008;8:243-52.
24. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005;11:5146-52.
25. Qin SL, Chen XJ, Xu X, Shou JZ, Bi XG, Ji L, et al. Detection of chromosomal alterations in bladder transitional cell carcinomas from Northern China by comparative genomic hybridization. Cancer Lett 2006;238:230-9.
26. Kim EJ, Kim WJ. The causal relationship between RUNX3 and bladder tumor. Korean J Urol 2005;46:1192-8.
27. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol 2008;180:1141-5.
28. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-75.
29. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-8.